Omnicell Gets a Hold Rating from Piper Jaffray

By Austin Angelo

Piper Jaffray analyst Sean Wieland reiterated a Hold rating on Omnicell (NASDAQ: OMCL) on July 28 and set a price target of $40. The company’s shares closed on Friday at $48.55, close to its 52-week high of $49.55.

According to, Wieland is a top 100 analyst with an average return of 25.1% and a 75.2% success rate. Wieland covers the Technology sector, focusing on stocks such as Tabula Rasa HealthCare, Medidata Solutions, and Quality Systems.

Omnicell has an analyst consensus of Strong Buy, with a price target consensus of $48.25.

The company has a one year high of $49.55 and a one year low of $30.35. Currently, Omnicell has an average volume of 215.5K.

Based on the recent corporate insider activity of 68 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Omnicell, Inc. engages in the provision of comprehensive automation, and business analytics software solutions for patient-centric medication and supply management. It operates through Automation and Analytics, and Medication Adherence segments.